Global Peptide and Anticoagulant Drugs Market: Advances in the treatment rate and recent approval of drugs are some of the impacting factors to accelerate the growth of peptide and anticoagulant drugs market.

Global peptide and anticoagulant drugs market size is expected to grow from USD 1455.6 million in 2020 to USD 1975.3 million by 2027, at a Compound Annual Growth Rate (CAGR) of 4.5 % during the forecast period. Anticoagulants are referred to as blood thinners. It is a chemical substance that prevents or reduces coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals; it helps to keep the bitten area unclotted long enough for the animal to obtain some blood.

The growth of peptide and anticoagulant drugs market enhanced by the growing cases of peptide and anticoagulant drugs which create an opportunity for the other pharma companies to introduce novel therapy and promising pipeline drugs. In addition, advances in the treatment rate and recent approval of drugs are some of the impacting factors to accelerate the growth of peptide and anticoagulant drugs market. Nevertheless, huge financial burden and patent expiration are the factors that hinder the growth of this market. Anticoagulants are related to and thrombolytic drugs and anti-platelet drugs by manipulating the various pathways of blood coagulation which inhibit platelet aggregation. These drugs are majorly used for deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. Peptides are long chain amino acids. Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of this market. Also, an increase in the rate of Diabetes and Cancer promotes the growth of the market. According, to WHO in 2017 diabetes patients has risen from 108 million in 1980 to 422 million in 2014.. Also predicted that breast cancer rates are highest in non-Hispanic white women, breast cancer death rates are highest in African American women which increase the growth of peptide and anticoagulant drugs market in the forecast period. However, the higher price of NOACs and lack of antidots for NOACs impede the market growth.

Peptide is the unique class of therapeutics which are composed of protein called amino acids joined together by a peptide bond. It is recognized that peptides therapeutics has key role in any biological event and therefore, it has high demand for pharmacological use while anticoagulant is a class of therapeutics that helps in reducing or preventing the blood coagulation. Clotting of blood is physiological action of the body which helps in controlling external bleeding during the time of injuries.

Some of the key players in the global peptide drugs market are Abbott Laboratories (U.S.), Cadila Pharmaceuticals (India), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), and Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India

Among regions, North America has been witnessing a positive growth for peptide and anticoagulant drugs market throughout the forecasted period owing to the global leaders in research and development activities, launch of drugs annually and increase in cases of chronic diseases. Europe is considered a second largest growing regional segment due to the presence of refined healthcare infrastructure and high diagnostic rate. Asia-Pacific leads the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.